MarketCap
Facebook
X
Telegram
ShockWave Medical Financial Ratios 2023-2011 | SWAV
Brief overview of ShockWave Medical's financial ratios
The comparison uses the five latest available annual observations between 2019 and 2023.
The latest available valuation ratios are EV/EBITDA 60.06x (median 56.38x), P/S 13.16x (median 22.35x), P/B 14.37x (median 14.37x). The combined ratio level is close to the company's five-year norm at a -7.7% deviation. No clear premium or discount is visible.
Capital efficiency is characterized by ROE 22%, ROA 9.4%, ROCE 23.8%. Business quality is high on return ratios, supporting the ability to create value.
The cash cycle lengthened by 185.2 days to 366.2 days. Operations require more funding.
What the ratios show
ShockWave Medical's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
65.2 | 31.6 | -680.9 | -58.8 | -18.8 | - | - | - | - | - | - | - | - |
P/S |
13.2 | 13.9 | 26.2 | 57.0 | 22.4 | - | - | - | - | - | - | - | - |
EPS |
4.0 | 6.0 | -0.3 | -2.0 | -2.1 | -23.4 | -19.7 | - | - | - | - | - | - |
EV (Enterprise Value) |
10.2 B | 6.8 B | 6.24 B | 3.86 B | 860 M | -16.4 M | 143 M | - | - | - | - | - | - |
EBITDA per Share |
4.62 | 3.59 | 0.08 | -1.93 | -2.11 | -23.1 | -19.6 | - | - | - | - | - | - |
EV/EBITDA |
60.1 | 52.7 | 2302.5 | -60.5 | -17.0 | 0.4 | -4.7 | - | - | - | - | - | - |
PEG |
0.08 | 0.04 | - | -6.07 | 11.02 | - | - | - | - | - | - | - | - |
P/B |
14.4 | 13.3 | 25.7 | 17.1 | 5.0 | - | - | - | - | - | - | - | - |
P/CF |
49.0 | 57.9 | 413.7 | -54.3 | -19.9 | - | - | - | - | - | - | - | - |
ROE % |
22.03 | 42.24 | -3.78 | -29.11 | -26.53 | 33.53 | 36.76 | - | - | - | - | - | - |
ROA % |
9.40 | 33.43 | -2.64 | -24.15 | -22.04 | -76.94 | -51.62 | - | - | - | - | - | - |
ROCE % |
23.79 | 24.28 | -0.36 | -29.10 | -24.93 | 37.77 | -56.36 | - | - | - | - | - | - |
Current Ratio |
1.7 | 4.8 | 3.3 | 5.9 | 5.9 | 2.3 | 0.4 | - | - | - | - | - | - |
DSO |
46.5 | 40.5 | 37.8 | 51.3 | 43.5 | 42.4 | - | - | - | - | - | - | - |
DIO |
349.5 | 331.6 | 320.8 | 364.6 | 183.0 | 129.2 | - | - | - | - | - | - | - |
DPO |
29.8 | 28.8 | 22.0 | 37.0 | 45.5 | 37.4 | - | - | - | - | - | - | - |
Operating Cycle |
396.0 | 372.1 | 358.6 | 415.9 | 226.5 | 171.6 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
366.2 | 343.4 | 336.6 | 378.9 | 181.0 | 134.1 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.48 | 0.95 | 0.79 | 1.07 | - | 0.97 | 0.71 | 410 | - | 0.06 | -0.01 | -0.68 | - | -0.38 | -0.56 | -0.59 | - | -0.46 | -0.38 | -1.37 | - | -5.73 | -5.79 | -5.63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
1.22 | 1.38 | 1 | 1.14 | - | 1.11 | 0.88 | 0.46 | - | 0.16 | 0.04 | -0.48 | - | -0.34 | -0.53 | -0.59 | - | -0.43 | -0.38 | -1.27 | - | -5.41 | -5.68 | -5.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
24.72 | 27.19 | 29.75 | 30.49 | 23.63 | 24.52 | 14.48 | -5.45 | -10.87 | -16.33 | -24.60 | -34.95 | -23.40 | -35.37 | -38.80 | -41.32 | -30.76 | -22.46 | -2.24 | 14.47 | 24.37 | 8.30 | 8.24 | 7.83 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
14.41 | 18.39 | 22.15 | 22.38 | 17.38 | 18.03 | 10.52 | -4.38 | -8.27 | -12.88 | -19.84 | -28.19 | -19.42 | -28.82 | -31.43 | -33.25 | -24.75 | -43.80 | -53.32 | -64.06 | -55.93 | -19.05 | -18.92 | -17.96 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
25.12 | 29.81 | 32.25 | 32.74 | 25.76 | 27.04 | 16.63 | -1.63 | -7.37 | -12.77 | -21.39 | -31.98 | -23.42 | -35.49 | -39.51 | -41.58 | -30.90 | -22.69 | -2.30 | 15.12 | 24.53 | 8.22 | 8.32 | 8.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.7 | 4.6 | 3.7 | 4.8 | 4.0 | 3.7 | 3.6 | 3.3 | 3.8 | 4.1 | 4.2 | 5.9 | 6.4 | 6.8 | 5.1 | 5.9 | 4.7 | 5.4 | 5.6 | 2.3 | 2.3 | 2.3 | 2.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
46.5 | 47.9 | 45.8 | 44.1 | - | 43.1 | 40.7 | 41.5 | - | 38.5 | 36.4 | 44.8 | - | 39.8 | 62.9 | 45.6 | - | 43.5 | 41.8 | 42.6 | - | 72.2 | 114.1 | 98.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
337.1 | 352.3 | 326.6 | 343.0 | - | 329.3 | 309.2 | 341.0 | - | 312.1 | 320.1 | 366.5 | - | 452.1 | 499.8 | 226.0 | - | 181.6 | 168.9 | 180.4 | - | 237.3 | 397.1 | 294.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
27.0 | 36.7 | 44.6 | 38.5 | - | 22.3 | 37.5 | 42.4 | - | 26.1 | 29.2 | 30.0 | - | 39.2 | 59.9 | 39.9 | - | 48.8 | 68.3 | 81.0 | - | 68.8 | 115.1 | 85.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
383.6 | 400.2 | 372.4 | 387.1 | - | 372.4 | 349.9 | 382.6 | - | 350.5 | 356.4 | 411.3 | - | 570.8 | 862.2 | 395.8 | - | 309.7 | 333.8 | 319.7 | - | 309.6 | 511.2 | 393.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
356.6 | 363.5 | 327.9 | 348.6 | - | 350.1 | 312.5 | 340.1 | - | 324.4 | 327.2 | 381.2 | - | 545.4 | 825.0 | 361.4 | - | 251.9 | 272.2 | 256.2 | - | 240.8 | 396.1 | 307.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company ShockWave Medical, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
China
Israel
Britain
Canada
